gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

ACPP acid phosphatase, prostate

prostatic acid phosphatase
Top mentioned proteins: ACID, PAP, HAD, CAN, MEN
Papers on prostatic acid phosphatase
Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.
Vihko et al., Helsinki, Finland. In Prostate, Feb 2016
We have previously shown in a murine model that prostatic acid phosphatase (PAP) deficiency leads to increased cell proliferation and development of prostate adenocarcinoma.
Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.
Aslanidi et al., Gainesville, United States. In J Immunother, Sep 2015
Our results document the suppression of subcutaneous tumor growth in animals immunized with AAV6-S663V+T492V vectors expressing prostatic acid phosphatase (PAP) for approximately 4 weeks in comparison with 1 week and 2 weeks for the negative controls, AAV6-EGFP, and AAV6-WT-PAP treated mice, respectively.
Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils.
Shorter et al., Philadelphia, United States. In Biol Open, 2014
Semen harbors amyloid fibrils formed by proteolytic fragments of prostatic acid phosphatase (PAP248-286 and PAP85-120) and semenogelins (SEM1 and SEM2) that potently enhance HIV infectivity.
Clear cell adenocarcinoma of the urethra: review of the literature.
Venyo, Manchester, United Kingdom. In Int J Surg Oncol, 2014
(iii) It is usually, readily distinguished from nephrogenic adenoma because of greater cytological a-typicality and mitotic activity and does not stain for prostate-specific antigen or prostatic acid phosphatase.
Studies on Chromatographic Fingerprint and Fingerprinting Profile-Efficacy Relationship of Saxifraga stolonifera Meerb.
Deng et al., Guiyang, China. In Molecules, 2014
The model was evaluated by analyzing prostatic index (PI), serum acid phosphatase (ACP) activity, concentrations of serum dihydrotestosterone (DHT), prostatic acid phosphatase (PACP) and type II 5α-reductase (SRD5A2).
A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.
Gambhir et al., Stanford, United States. In Plos One, 2014
To address this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quantitate prostate specific antigen (PSA; free and total), prostatic acid phosphatase, carbonic anhydrase 1 (CA1), osteonectin, IL-6 soluble receptor (IL-6sr), and spondin-2.
Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities.
Yegutkin, Turku, Finland. In Crit Rev Biochem Mol Biol, 2014
The duration and magnitude of purinergic signaling is governed by a network of ectoenzymes, including the enzymes of the nucleoside triphosphate diphosphohydrolase (NTPDase) family, the nucleotide pyrophosphatase/phosphodiesterase (NPP) family, ecto-5'-nucleotidase/CD73, tissue-nonspecific alkaline phosphatase (TNAP), prostatic acid phosphatase (PAP) and other alkaline and acid phosphatases, adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP).
Prostate cancer vaccines in combination with additional treatment modalities.
Lubaroff et al., Iowa City, United States. In Immunol Res, 2014
Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase.
Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.
Lin et al., Omaha, United States. In Biochim Biophys Acta, 2014
Cellular prostatic acid phosphatase (cPAcP) is a prostate-specific differentiation antigen.
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Fong et al., San Francisco, United States. In Curr Treat Options Oncol, 2014
Sipuleucel-T is an autologous cellular therapy, which primes autologous antigen-presenting cells against the prostatic acid phosphatase (PAP) antigen.
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
Wilding et al., Madison, United States. In J Clin Oncol, 2009
PURPOSE: Prostatic acid phosphatase (PAP) is a prostate tumor antigen.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Hershberg et al., San Francisco, United States. In J Clin Oncol, 2006
PURPOSE: Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase.
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
Valone et al., San Francisco, United States. In J Clin Oncol, 2001
PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor.
Mechanism-based inactivation of prostatic acid phosphatase.
Widlanski et al., Bloomington, United States. In Science, 1993
By extrapolation from data on inhibitors of other types of hydrolases, an inhibitor of prostatic acid phosphatase was designed that is likely to function as a mechanism-based phosphotyrosine phosphatase inactivator.
Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging.
Mahan et al., In Jama, 1983
Radioimmunodetection (RAID) of prostatic cancer is done by injecting 131I-labeled rabbit antibody IgG against prostatic acid phosphatase (PAP) and performing total-body photoscans with a gamma scintillation camera.
share on facebooktweetadd +1mail to friends